Treatment patterns and outcomes in KRAS-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.

Objectives: KRAS mutations, particularly KRAS, are prevalent in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have been a frontline treatment, but recently developed KRAS-selective inhibitors, such as sotorasib, present new therapeutic options. We conducted a multi-center retrospective cohort study to gain insights into real-world treatment patterns and outcomes in patients with KRAS-positive advanced NSCLC receiving systemic therapy post-ICI treatment.

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for Mutation-Positive Patients Treated with First-Line Osimertinib.

The use of osimertinib in the first-line (1L) setting is an effective treatment option for sensitizing -mutations (m+) and has significantly altered the standard of care practice for m+ disease in Canada. Unfortunately, acquired resistance to osimertinib is almost universal, and outcomes are disparate. Post-progression treatment patterns and the outcome of real-world Canadian m+ patients receiving 1L osimertinib were the focus of this retrospective review.